Axogen, Inc. (AXGN)

NASDAQ: AXGN · IEX Real-Time Price · USD
10.00
0.48 (5.04%)
At close: May 20, 2022 4:00 PM
9.99
-0.01 (-0.10%)
After-hours:May 20, 2022 7:02 PM EDT
Market Cap419.81M
Revenue (ttm)127.33M
Net Income (ttm)-31.80M
Shares Out41.98M
EPS (ttm)-0.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume294,409
Open9.68
Previous Close9.52
Day's Range9.48 - 10.06
52-Week Range6.87 - 22.82
Beta0.74
AnalystsBuy
Price Target19.38 (+93.8%)
Earnings DateMay 4, 2022

About AXGN

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM...

IndustryHealth Care Equipment & Supplies
Employees428
Stock ExchangeNASDAQ
Ticker SymbolAXGN
Full Company Profile

Financial Performance

In 2021, Axogen's revenue was $127.36 million, an increase of 13.41% compared to the previous year's $112.30 million. Losses were -$26.99 million, 13.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AXGN stock is "Buy." The 12-month stock price forecast is 19.38, which is an increase of 93.80% from the latest price.

Price Target
$19.38
(93.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Axogen Aces Phase 3 Study For Avance Nerve Graft

Axogen Inc (NASDAQ: AXGN) announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries.  Avance Nerve Graft is a biologically active off-the...

2 weeks ago - Benzinga

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Axogen, Inc Reports 2022 First Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, toda...

2 weeks ago - GlobeNewsWire

Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft

RECON achieved its Primary Endpoint, a critical milestone toward transitioning Avance Nerve Graft to a licensed biologic and further supporting the expanded adoption of Avance RECON achieved its Primary...

2 weeks ago - GlobeNewsWire

Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022

ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

1 month ago - GlobeNewsWire

Axogen, Inc. publishes inaugural ESG Report

ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...

2 months ago - GlobeNewsWire

AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results

ALACHUA, Fla. and TAMPA, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...

2 months ago - GlobeNewsWire

Earnings Preview: AxoGen (AXGN) Q4 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Axogen to Participate at Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...

3 months ago - GlobeNewsWire

Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022

ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...

3 months ago - GlobeNewsWire

Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings

Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for nerv...

4 months ago - GlobeNewsWire

Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation

ALACHUA, Fla. and TAMPA, Fla., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...

5 months ago - GlobeNewsWire

Axogen, Inc. to Participate at Jefferies London Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...

6 months ago - GlobeNewsWire

AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Axogen: Q3 Earnings Insights

Axogen (NASDAQ:AXGN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

Axogen, Inc. Reports 2021 Third Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...

6 months ago - GlobeNewsWire

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021

ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...

7 months ago - GlobeNewsWire

Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand

Industry leading nerve repair surgeons will share best practices and case studies during symposium session Industry leading nerve repair surgeons will share best practices and case studies during sympos...

7 months ago - GlobeNewsWire

Axogen RECON(SM) Clinical Study Completes Subject Follow-up

RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Av...

8 months ago - GlobeNewsWire

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and 3.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Axogen, Inc. Reports 2021 Second Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...

9 months ago - GlobeNewsWire

AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to per...

9 months ago - GlobeNewsWire